ALECTOR
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimerโs disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alectorโs strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in disco... very and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.
ALECTOR
Industry:
Biotechnology Genetics Health Care Therapeutics
Founded:
2013-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.alector.com
Total Employee:
101+
Status:
Active
Contact:
(415) 231-5660
Email Addresses:
[email protected]
Total Funding:
194.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Apton Biosystems
Apton Biosystems develops a high-throughput and low-cost sequencing platform that revolutionizes the availability of genetic analysis.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
OrbiMed
OrbiMed investment in Series E - Alector
Mission Bay Capital
Mission Bay Capital investment in Series E - Alector
Euclidean Capital
Euclidean Capital investment in Series E - Alector
GV
GV investment in Series E - Alector
Polaris Partners
Polaris Partners investment in Series E - Alector
Section 32
Section 32 investment in Series E - Alector
Deerfield Capital Management
Deerfield Capital Management investment in Series E - Alector
Amgen Ventures
Amgen Ventures investment in Series E - Alector
Mission BioCapital
Mission BioCapital investment in Series E - Alector
Casdin Capital
Casdin Capital investment in Series E - Alector
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2019-02-07 | INmuneBIO | Alector investment in Post-IPO Equity - INmuneBIO | 8.17 M USD |
Official Site Inspections
http://www.alector.com Semrush global rank: 3.92 M Semrush visits lastest month: 3.21 K
- Host name: 23.185.0.3
- IP address: 23.185.0.3
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago